Comparative Pharmacology
Head-to-head clinical analysis: MONOFERRIC versus SESQUIENT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MONOFERRIC versus SESQUIENT.
MONOFERRIC vs SESQUIENT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Monomeric ferric iron replaces iron stores and is incorporated into hemoglobin, myoglobin, and enzymes, supporting erythropoiesis and oxygen transport.
SESQUIENT is a monoclonal antibody that binds to the IL-23 receptor, inhibiting IL-23-mediated signaling and subsequent activation of inflammatory pathways involved in psoriasis and psoriatic arthritis.
100-200 mg elemental iron intravenously as a single dose, repeated weekly until iron stores are replete. Typical total dose is 1-2 g.
Intravenous injection of 20 mg/m² body surface area once every 3 weeks.
None Documented
None Documented
Terminal half-life: 10-14 hours for ferric carboxymaltose core; clinical effect persists for weeks due to iron utilization
12 hours (range 10-14 h); allows twice-daily dosing in most patients; prolonged in renal impairment
Renal: <1% unchanged; Biliary/fecal: >99% as iron in RBC turnover and storage
Renal: 80% unchanged; Biliary/Fecal: 15% as metabolites; 5% other
Category C
Category C
Iron Supplement
Iron Supplement